Exicure to Present at the AACR Annual Meeting 2019

Two posters are being presented at the AACR Annual Meeting in
Atlanta, Georgia
Exicure’s TLR9 agonist shows activation of
NK cells and T cells in a Phase 1 clinical trial
Data
presented in collaboration with Celldex show that Exicure’s technology
leads to a more potent anti-tumor response when combined with Celldex’s
CDX-301

SKOKIE, Ill.–(BUSINESS WIRE)–Exicure, Inc. (OTCQB:XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, will present pre-clinical and clinical data for its TLR9
immune system agonist, AST-008, in two poster sessions at the AACR
Annual Meeting 2019 in Atlanta, Georgia from March 29 – April 03, 2019.

“On behalf of the Exicure team, we are pleased to announce these two
posters which underscore the importance of Exicure’s SNA technology for
immune therapy against cancer,” said Dr. David Giljohann, Chief
Executive Officer of Exicure. “The first poster shows the high potency
activation of effector immune cells by our immune system agonist AST-008
after administration of AST-008 to healthy volunteers in a Phase 1
clinical trial. In the second poster, we are pleased to share for the
first time, work conducted in collaboration with Celldex Therapeutics
showing that Exicure’s TLR9 agonist leads to improved anti-tumor
response when combined with CDX-301,” said Dr. Giljohann.

The first poster, authored and presented by Exicure scientists, titled: “AST-008,
a TLR9 agonist spherical nucleic acid, activated NK cells, T cells, and
cytokines in healthy subjects in a Phase 1 clinical trial”
demonstrates the utility of Exicure’s proprietary platform technology
for targeting TLR9 to upregulate the immune system. Exicure’s drug,
AST-008, is now enrolling patients in a Phase 1b/2 trial in patients
with advanced solid tumors.

A second poster, to be presented by Celldex scientists, showcases data
generated by Celldex Therapeutics, Inc. and Exicure through an ongoing
scientific collaboration. The poster, titled: “Preclinical evaluation
of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and
AST-008, a TLR9 agonist SNA” highlights improved anti-tumor activity
after administration of AST-008 in combination with CDX-301.

Details of the posters:

Title: AST-008, a TLR9 agonist spherical nucleic acid,
activated NK cells, T cells, and cytokines in healthy subjects in a
Phase 1 clinical trial.
Abstract/Poster No: CT044/1
Date
of poster presentation: April 01, 2019, 8:00 AM – 12:00 PM ET
Session
Location: Georgia World Congress Center, Exhibit Hall B, Poster
Section 17

Title: Preclinical evaluation of the recombinant dendritic
cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA
Abstract/Poster
No: 3217/27
Date of poster presentation: April 02, 2019,
8:00 AM – 12:00 PM ET
Session Location: Georgia World
Congress Center, Exhibit Hall B, Poster Section 23

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing
therapeutics for immuno-oncology, inflammatory diseases and genetic
disorders based on our proprietary Spherical Nucleic Acid, or SNA
technology. We believe Exicure’s proprietary SNA architecture has
distinct chemical and biological properties that may provide advantages
over other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure’s lead program is in a Phase1b/2 trial in patients
with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com

Forward Looking Statements

This press release contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange Act
of 1934, as amended, and Section 27A of the United States Securities Act
of 1933, as amended) concerning the Company, the Company’s technology,
potential therapies, cash requirements and other matters.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,” “would,”
“expect,” “plan,” “believe,” “intend,” “look forward,” and other similar
expressions among others. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors, including,
without limitation: unexpected costs, charges or expenses that reduce
cash runway; that Exicure’s pre-clinical or clinical programs do not
advance or result in approved products on a timely or cost effective
basis or at all; the cost, timing and results of clinical trials; that
many drug candidates that have completed Phase 1 trials do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; regulatory developments; and the ability of Exicure
to protect its intellectual property rights. Risks facing the Company
and its programs are set forth in the Company’s filings with the SEC.
Except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to make
any other forward-looking statements, whether as a result of new
information, future events or otherwise.

Contacts

Media:
MacDougall
Karen Sharma
781-235-3060
[email protected]